(CercleFinance.com) – The FDA announced on Wednesday that it had granted orphan drug status to fenfluramine hydrochloride, a drug belonging to UCB’s portfolio, for the treatment of epileptic seizures.
More specifically, the US health authority’s decision applies to the treatment of CDKL5 deficiency disorder, a rare disease of genetic origin.
This designation of orphan drug by the Food & Drug Administration could in particular allow Zogenix, the subsidiary of UCB at the origin of the file, to obtain a priority review.
This status, granted to new treatments for diseases or conditions affecting less than 200,000 people in the United States, could also give it the benefit of commercial exclusivity for seven years in the event of FDA approval.
Following this information, the UCB share posted the strongest rise in the BEL 20 index of the Brussels Stock Exchange with gains of almost 2%.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
